{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:54:18Z","timestamp":1794646458251,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1046-y","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T01:04:15Z","timestamp":1423616655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing"],"prefix":"10.1186","volume":"15","author":[{"given":"Lucia","family":"Cavelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ameur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"H\u00e4ggqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"H\u00f6ijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"issue":"6","key":"1046_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"17","key":"1046_CR2","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","volume":"116","author":"DW Sherbenou","year":"2010","unstructured":"Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010;116(17):3278\u201385.","journal-title":"Blood"},{"issue":"9","key":"1046_CR3","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1073\/pnas.1321173111","volume":"111","author":"DL Gibbons","year":"2014","unstructured":"Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014;111(9):3550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1046_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489\u201398.","journal-title":"Blood"},{"issue":"3","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"issue":"1","key":"1046_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12032-010-9781-z","volume":"29","author":"FX Gruber","year":"2012","unstructured":"Gruber FX, Lundan T, Goll R, Silye A, Mikkola I, Rekvig OP, et al. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med Oncol. 2012;29(1):219\u201326.","journal-title":"Med Oncol"},{"issue":"6","key":"1046_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/leu.2008.65","volume":"22","author":"DW Sherbenou","year":"2008","unstructured":"Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22(6):1184\u201390.","journal-title":"Leukemia"},{"issue":"4","key":"1046_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejca.2013.11.030","volume":"50","author":"R Kastner","year":"2014","unstructured":"Kastner R, Zopf A, Preuner S, Proll J, Niklas N, Foskett P, et al. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur J Cancer. 2014;50(4):793\u2013800.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634\u201348.","journal-title":"Blood"},{"issue":"5910","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1126\/science.1162986","volume":"323","author":"J Eid","year":"2009","unstructured":"Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133\u20138.","journal-title":"Science"},{"issue":"6","key":"1046_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/gb-2013-14-6-405","volume":"14","author":"RJ Roberts","year":"2013","unstructured":"Roberts RJ, Carneiro MO, Schatz MC. The advantages of SMRT sequencing. Genome Biol. 2013;14(6):405.","journal-title":"Genome Biol"},{"issue":"2","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","volume":"10","author":"J Laudadio","year":"2008","unstructured":"Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn: JMD. 2008;10(2):177\u201380.","journal-title":"J Mol Diagn: JMD"},{"issue":"1","key":"1046_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1182\/blood-2014-05-573485","volume":"124","author":"WT Parker","year":"2014","unstructured":"Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood. 2014;124(1):153\u20135.","journal-title":"Blood"},{"issue":"12","key":"1046_CR14","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","volume":"7","author":"TS Lee","year":"2008","unstructured":"Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008;7(12):3834\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1751-553X.2010.01291.x","volume":"33","author":"W Ma","year":"2011","unstructured":"Ma W, Giles F, Zhang X, Wang X, Zhang Z, Lee TS, et al. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int J Lab Hematol. 2011;33(3):326\u201331.","journal-title":"Int J Lab Hematol"},{"issue":"19","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","volume":"118","author":"T O\u2019Hare","year":"2011","unstructured":"O\u2019Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, et al. The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011;118(19):5250\u20134.","journal-title":"Blood"},{"issue":"11","key":"1046_CR17","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1158\/1535-7163.MCT-10-0595","volume":"9","author":"JB Gaillard","year":"2010","unstructured":"Gaillard JB, Arnould C, Bravo S, Donadio D, Exbrayat C, Jourdan E, et al. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2010;9(11):3083\u20139.","journal-title":"Mol Cancer Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1046-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T12:44:29Z","timestamp":1551185069000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1046-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]},"article-number":"45"}}